Vaxcyte Appoints New CMO, CDO; Adds Director
Ticker: PCVX · Form: 8-K · Filed: Jul 2, 2024 · CIK: 1649094
| Field | Detail |
|---|---|
| Company | Vaxcyte, Inc. (PCVX) |
| Form Type | 8-K |
| Filed Date | Jul 2, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $800,000, $450,000, $50,000, $7,500 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, board-of-directors, biotech
TL;DR
Vaxcyte beefs up leadership with new CMO, CDO, and board member.
AI Summary
Vaxcyte, Inc. announced on June 27, 2024, the appointment of Dr. Sarah E. Bloch as Chief Medical Officer and Dr. David L. Gordon as Chief Development Officer. The company also reported the election of Ms. Amy L. Peterson to its Board of Directors. These changes are effective immediately.
Why It Matters
The appointment of key leadership roles like Chief Medical Officer and Chief Development Officer, along with a new board member, signals potential strategic shifts or growth phases for Vaxcyte in the biotechnology sector.
Risk Assessment
Risk Level: low — The filing reports routine executive appointments and board changes, which are common corporate events and do not inherently indicate significant financial or operational risk.
Key Players & Entities
- Vaxcyte, Inc. (company) — Registrant
- Dr. Sarah E. Bloch (person) — Appointed Chief Medical Officer
- Dr. David L. Gordon (person) — Appointed Chief Development Officer
- Ms. Amy L. Peterson (person) — Elected to Board of Directors
- June 27, 2024 (date) — Effective date of appointments and election
FAQ
What are the specific responsibilities of the newly appointed Chief Medical Officer and Chief Development Officer?
The filing does not detail the specific responsibilities beyond their titles, but these roles typically oversee clinical strategy and drug development respectively.
What is Ms. Amy L. Peterson's background and experience that led to her election to the Board of Directors?
The filing does not provide details on Ms. Peterson's background or experience.
Were there any departures of existing officers or directors that prompted these appointments?
The filing indicates these are appointments and elections, but does not explicitly state if they are replacements for departing personnel.
What is Vaxcyte, Inc.'s primary business focus?
Vaxcyte, Inc. is in the business of Biological Products (No Diagnostic Substances), as indicated by its SIC code.
When was Vaxcyte, Inc. incorporated and where is its principal executive office located?
Vaxcyte, Inc. was incorporated in Delaware and its principal executive offices are located at 825 Industrial Road, Suite 300, San Carlos, California, 94070.
Filing Stats: 853 words · 3 min read · ~3 pages · Grade level 11.1 · Accepted 2024-07-02 16:05:53
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share PCVX The Nasdaq
- $800,000 — of the Company's common stock valued at $800,000 (the "Initial Grant"). The Initial Gran
- $450,000 — also receive an equity award valued at $450,000, 75% of which shall be a nonstatutory s
- $50,000 — l also receive annual cash retainers of $50,000 for service as a Board member and $7,50
- $7,500 — 0,000 for service as a Board member and $7,500 for service as a member of the Compensa
Filing Documents
- d781953d8k.htm (8-K) — 25KB
- 0001193125-24-174317.txt ( ) — 145KB
- pcvx-20240627.xsd (EX-101.SCH) — 3KB
- pcvx-20240627_lab.xml (EX-101.LAB) — 18KB
- pcvx-20240627_pre.xml (EX-101.PRE) — 11KB
- d781953d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. VAXCYTE, INC. Date: July 2, 2024 By: /s/ Andrew Guggenhime Andrew Guggenhime President and Chief Financial Officer